HIKMA (LON:HIK) Director/PDMR Shareholding

Directive transparence : information réglementée Communiqué sur comptes, résultats, chiffres d’affaires

17/05/2018 13:45
Hikma Pharmaceuticals Plc  -  HIK   

Director/PDMR Shareholding


Released 13:45 17-May-2018

 


Hikma Pharmaceuticals PLC - EIP Awards


 


LONDON, 17 May 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)

(LEI: 549300BNS685UXH4JI75)
announces that the Remuneration Committee has made the following conditional awards and nil cost option under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.


 


Awards under the EIP were made on 16 May 2018 at a price of 1,035 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2017, in accordance with the EIP rules) as follows:


Notification and public disclosure of transactions by persons discharging managerial responsibilities


Mazen Darwazah













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Mazen Darwazah



2



Reason for the notification



a)



Position/status



Executive Vice Chairman



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 16,953



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



Mazen Darwazah













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Mazen Darwazah



2



Reason for the notification



a)



Position/status



Executive Vice Chairman



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 12,042



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



Bassam Kanaan













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Bassam Kanaan



2



Reason for the notification



a)



Position/status



Chief Strategy and Corporate Development Officer



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 25,729



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



Bassam Kanaan













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Bassam Kanaan



2



Reason for the notification



a)



Position/status



Chief Strategy and Corporate Development Officer



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 25,729



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



Khalid Nabilsi













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Khalid Nabilsi



2



Reason for the notification



a)



Position/status



Chief Financial Officer



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 23,062



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



Khalid Nabilsi













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Khalid Nabilsi



2



Reason for the notification



a)



Position/status



Chief Financial Officer



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 23,062



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



 


Riad Mishlawi













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Riad Mishlawi



2



Reason for the notification



a)



Position/status



CEO, Injectables Division



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 22,601



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



 


 


 


Riad Mishlawi













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Riad Mishlawi



2



Reason for the notification



a)



Position/status



CEO, Injectables Division



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 22,601



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



 


 


 


Majda Labadi













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Majda Labadi



2



Reason for the notification



a)



Position/status



Chief Human Capital Officer



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 15,855



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



 


 


 


Majda Labadi













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Majda Labadi



2



Reason for the notification



a)



Position/status



Chief Human Capital Officer



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 15,855



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



 


 


 


Susan Ringdal













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Susan Ringdal



2



Reason for the notification



a)



Position/status



Vice President, Corporate Strategy and Investor Relations



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 14,257



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



 


 


 


Susan Ringdal













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Susan Ringdal



2



Reason for the notification



a)



Position/status



Vice President, Corporate Strategy and Investor Relations



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 14,257



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



 


 


 


Brian Hoffman













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Brian Hoffmann



2



Reason for the notification



a)



Position/status



President, US Generics Division



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 18,247



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



 


 


 


Bryan Hotston













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Bryan Hotston



2



Reason for the notification



a)



Position/status



Chief Information Officer



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 17,016



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



 


 


 


Hussein Arkhagha













































































1



Details of the person discharging managerial responsibilities / person closely associated



a)



Name



Hussein Arkhagha



2



Reason for the notification



a)



Position/status



General Counsel



b)



Initial notification /Amendment



Initial notification



3



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a)



Name



Hikma Pharmaceuticals PLC



b)



LEI



549300BNS685UXH4JI75



4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



a)



Description of the financial instrument, type of instrument and identification code



Description: Ordinary shares of 10 pence each (Shares)


ID Code: GB00B0LCW083



b)



Nature of the transaction


 



The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years



c)



Price(s) and volume(s)



Price(s): £10.35


Volume(s): 13,489



d)



Aggregated information



N/A



e)



Date of the transaction



16 May 2018



f)



Place of the transaction



London Stock Exchange (XLON)



 


Peter Speirs

Company Secretary, responsible for releasing this announcement

+44 (0) 20 7399 2760